Shares in Japanese biopharma venture AnGes Inc. continued to surge Tuesday, as its much-hyped coronavirus vaccine candidate moved closer to starting human trials.
Shares jumped as much as 19 percent in Tokyo trading, taking its gaining streak to a fourth day, after the Nikkei newspaper reported late Monday that it would begin clinical trials for its DNA vaccine in July, earlier than previously planned. The stock closed at the highest level since 2008.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.